Accordingly, clinicians are encouraged to record and track the patient's height and weight (BMI) before and during treatment and to encourage patients to self-monitor weight change by charting their weight.[6] Follow-up monitoring is additionally recommended at various intervals depending on the measure being evaluated. Fasting plasma glucose and blood pressure are assessed at baseline, at 3 months, and then annually, while lipids are assessed at baseline, at 3 months, and then every 5 years. If patients are at higher risk to develop DM or hypertension, more frequent monitoring is advised. Using these measures, clinicians can better assess patients' baseline status for weight (overweight defined as BMI 25–29), prediabetes (fasting plasma glucose 100–125 mg/dL) or DM (fasting plasma glucose ≥126 mg/dL), hypertension (>140/90 mmHg), or dyslipidemia to help determine their risk status and the contribution and/or causation of antipsychotic therapy.[6]